These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6178284)

  • 1. Human leukocyte interferon therapy for advanced ovarian carcinoma.
    Einhorn N; Cantell K; Einhorn S; Strander H
    Am J Clin Oncol; 1982 Apr; 5(2):167-72. PubMed ID: 6178284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
    Cancer Res; 1985 Sep; 45(9):4447-53. PubMed ID: 4028027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer activity of lymphoid cells isolated from human ascitic ovarian tumors.
    Mantovani A; Allavena P; Sessa C; Bolis G; Mangioni C
    Int J Cancer; 1980 May; 25(5):573-82. PubMed ID: 6154662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer cell cytotoxic potential of patients with ovarian carcinoma and its modulation with virus-modified tumor cell extract.
    Lotzová E; Savary CA; Freedman RS; Bowen JM
    Cancer Immunol Immunother; 1984; 17(2):124-9. PubMed ID: 6205745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further experience in testing the sensitivity of human ovarian carcinoma cells to interferon in an in vitro semisolid agar culture system: comparison of solid and ascitic forms of the tumor.
    Epstein LB; Shen JT; Abele JS; Reese CC
    Prog Clin Biol Res; 1980; 48():277-90. PubMed ID: 6163159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients.
    da Silva RF; Yoshida A; Cardozo DM; Jales RM; Paust S; Derchain S; Guimarães F
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28513532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon effect on cytotoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells.
    Allavena P; Introna M; Sessa C; Mangioni C; Mantovani A
    J Natl Cancer Inst; 1982 Apr; 68(4):555-62. PubMed ID: 6175786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulation of natural killer cell activity and inhibition of proliferation of various leukemic cells by purified human leukocyte interferon subtypes.
    Lee SH; Kelley S; Chiu H; Stebbing N
    Cancer Res; 1982 Apr; 42(4):1312-6. PubMed ID: 6174222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The interferon-natural killer cell system of patients with ovarian tumors].
    Sorokin AM; Moiseeva NB; Cheredeev AN; Frolova IS
    Akush Ginekol (Mosk); 1988 May; (5):23-7. PubMed ID: 2459982
    [No Abstract]   [Full Text] [Related]  

  • 10. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
    Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
    Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumors.
    Allavena P; Zanaboni F; Rossini S; Merendino A; Bonazzi C; Vassena L; Mangioni C; Mantovani A
    J Natl Cancer Inst; 1986 Oct; 77(4):863-8. PubMed ID: 3489856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneal administration of interferon beta in ovarian cancer patients.
    Rambaldi A; Introna M; Colotta F; Landolfo S; Colombo N; Mangioni C; Mantovani A
    Cancer; 1985 Jul; 56(2):294-301. PubMed ID: 2408731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of effects of leukocyte and fibroblast interferon on immunological parameters in cancer patients.
    Lucero MA; Magdelenat H; Fridman WH; Pouillart P; Billardon C; Billiau A; Cantell K; Falcoff E
    Eur J Cancer Clin Oncol; 1982 Mar; 18(3):243-51. PubMed ID: 6178592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mononuclear-cell infiltration in ovarian cancer. II. Immune function of tumour and ascites-derived inflammatory cells.
    Haskill S; Koren H; Becker S; Fowler W; Walton L
    Br J Cancer; 1982 May; 45(5):737-46. PubMed ID: 6177328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells.
    Allavena P; Peccatori F; Maggioni D; Erroi A; Sironi M; Colombo N; Lissoni A; Galazka A; Meiers W; Mangioni C
    Cancer Res; 1990 Nov; 50(22):7318-23. PubMed ID: 2121337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells.
    Nham T; Poznanski SM; Fan IY; Shenouda MM; Chew MV; Lee AJ; Vahedi F; Karimi Y; Butcher M; Lee DA; Hirte H; Ashkar AA
    Cancer Immunol Immunother; 2018 Apr; 67(4):575-587. PubMed ID: 29299659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal administration of Corynebacterium parvum in patients with ascitic ovarian tumors resistant to chemotherapy: effects on cytotoxicity of tumor-associated macrophages and NK cells.
    Mantovani A; Sessa C; Peri G; Allavena P; Introna M; Polentarutti N; Mangioni C
    Int J Cancer; 1981; 27(4):437-46. PubMed ID: 6168590
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumoricidal activity of macrophages isolated from human ascitic and solid ovarian carcinomas: augmentation by interferon, lymphokines and endotoxin.
    Peri G; Polentarutti N; Sessa C; Mangioni C; Mantovani A
    Int J Cancer; 1981 Aug; 28(2):143-52. PubMed ID: 6172388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Human natural killer activity in selected test systems and tissue compartments: natural killer cell modulation by biological response modifiers].
    Klappacher G
    Wien Klin Wochenschr; 1988 Nov; 100(22):743-6. PubMed ID: 3149079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.